Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Schoenberg

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
The Journal of Urology|September 6, 2006
Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladderPierre I Karakiewicz, Shahrokh F Shariat, Ganesh S Palapattu, et al.
Urology|April 10, 2014
Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder: a retrospective study of patients treated using radical cystectomyNilda Gonzalez-Roibon, Jenny J Kim, Sheila F Faraj, et al.
Urology|July 29, 2014
Reply by the authorsJonathan Jarow, Paul G Kluetz, Seth P Lerner, et al.
The Journal of Urology|December 6, 2017
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter StudySiamak Daneshmand, Sanjay Patel, Yair Lotan, et al.
Urology|December 17, 2013
Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshopJonathan P Jarow, Seth P Lerner, Paul G Kluetz, et al.
BJU International|May 6, 2008
Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control studyJochen Walz, Shahrokh F Shariat, Nazareno Suardi, et al.
The Journal of Urology|August 7, 2023
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)Sandip M Prasad, William C Huang, Neal D Shore, et al.
BJU International|July 7, 2018
Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre studyAngela B Smith, Siamak Daneshmand, Sanjay Patel, et al.
Urologic Oncology|June 24, 2022
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center studyKamal S Pohar, Sanjay Patel, Yair Lotan, et al.
The Journal of Urology|March 20, 2010
Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patientsDerya Tilki, Oliver Reich, Robert S Svatek, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
The Journal of Urology|September 6, 2006
Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladderPierre I Karakiewicz, Shahrokh F Shariat, Ganesh S Palapattu, et al.
Urology|April 10, 2014
Insulin-like growth factor-1 receptor overexpression is associated with outcome in invasive urothelial carcinoma of urinary bladder: a retrospective study of patients treated using radical cystectomyNilda Gonzalez-Roibon, Jenny J Kim, Sheila F Faraj, et al.
Urology|July 29, 2014
Reply by the authorsJonathan Jarow, Paul G Kluetz, Seth P Lerner, et al.
The Journal of Urology|December 6, 2017
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter StudySiamak Daneshmand, Sanjay Patel, Yair Lotan, et al.
Urology|December 17, 2013
Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshopJonathan P Jarow, Seth P Lerner, Paul G Kluetz, et al.
BJU International|May 6, 2008
Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control studyJochen Walz, Shahrokh F Shariat, Nazareno Suardi, et al.
The Journal of Urology|August 7, 2023
Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)Sandip M Prasad, William C Huang, Neal D Shore, et al.
BJU International|July 7, 2018
Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre studyAngela B Smith, Siamak Daneshmand, Sanjay Patel, et al.
Urologic Oncology|June 24, 2022
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center studyKamal S Pohar, Sanjay Patel, Yair Lotan, et al.
The Journal of Urology|March 20, 2010
Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patientsDerya Tilki, Oliver Reich, Robert S Svatek, et al.
Pageof 7